Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases

Goricar Katja; Kovac Viljem; Dodic-Fikfak Metoda; Dolzan Vita; Franko Alenka

doi:10.2478/raon-2020-0011

Radiology and Oncology (Mar 2020)

Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases

Goricar Katja,
Kovac Viljem,
Dodic-Fikfak Metoda,
Dolzan Vita,
Franko Alenka

Affiliations

Goricar Katja: Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Kovac Viljem: Institute of Oncology Ljubljana, Ljubljana, Slovenia
Dodic-Fikfak Metoda: Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Dolzan Vita: Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Franko Alenka: Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

DOI: https://doi.org/10.2478/raon-2020-0011
Journal volume & issue: Vol. 54, no. 1
pp. 86 – 95

Abstract

Read online

Asbestos exposure is associated with increased risk of several diseases, including malignant mesothelioma (MM). Cell surface glycoprotein mesothelin is overexpressed in MM and serum soluble mesothelin-related peptides (SMRP) were already proposed as a diagnostic or prognostic biomarker in MM. However, interindividual variability in serum SMRP levels limits the clinical usefulness. Our primary objective was to investigate the influence of MSLN rs1057147 on serum SMRP levels in asbestos-exposed subjects and patients with asbestos-related diseases as well as on survival in MM.

Published in Radiology and Oncology

ISSN: 1581-3207 (Online)
Publisher: Sciendo
Country of publisher: Slovenia
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
Website: https://sciendo.com/journal/RAON

About the journal

Abstract

Keywords